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Abstract
Background: Triple-negative breast cancer (TNBC) has aggressive progression with poor prognosis and ineffective
treatments. Selumetinib is an allosteric, ATP-noncompetitive inhibitor of MEK1/2, which has benn known as effective
antineoplastic drugs for several malignant tumors. We hypothesized that Selumetinib might be potential drug for TNBC
and explore the mechanism.
Methods: After treated with Selumetinib, the viability and mobility of HCC1937 and MDA-MB-231 were detected by
MTT, tunnel, wound-healing assay, transwell assay and FCM methods. MiR array was used to analysis the change of
miRs. We predicted and verified CUL1 is the target of miR-302a using Luciferase reporter assay. We also silenced the
CUL1 by siRNA, to clarify whether CUL1 take part in the cell proliferation, migration and regulated its substrate TIMP1
and TRAF2. Moreover, after transfection, the antagomir of miR-302a and CUL1 over-expressed plasmid into HCC1937
and MDA-MB-231 cell accompanied with the Selumetinib treatment, we detected the proliferation and migration again.
Results: Selumetinib reduce the proliferation, migration, triggered apoptosis and G1 arrest in TNBC cell lines. In this
process, the miR-302a was up-regulated and inhibited the CUL1 expression. The later negatively regulated the TIMP1
and TRAF2. As soon as we knockdown miR-302a and over-expression CUL1 in TNBC cells, the cytotoxicity of Selumetinib
was reversed.
Conclusions: MiR-302a targeted regulated the CUL1 expression and mediated the Selumetinib-induced cytotoxicity of
triple-negative breast cancer.
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Mini-Abstract
Selumetinib inhibited the proliferation and migration of
TNBC cell.
Background
Breast cancer is one of the most common cancer deaths
in female. Estrogen receptor(ER)-negative breast cancer
constitutes approximately 30 % of breast cancer cases.
Triple-negative is defined as a subgroup with ER,
PR(progesterone receptor) and human epidermal growth
factor receptor 2 (HER2) all negative. TNBC are as-
sumed importance for its molecular characters, aggres-
sive progress and distinct tranfer ability [1, 2]. Beneficial
results of current anti-HER2 or hormonal therapy could
not improve the curative effect of chemotherapy. In the
absence of proper treatments, TNBC often progresses to
metastatic lesions in the brain and lung in three years.
Once being with metastasis, the 5-year survival rate of
TNBC would be less than 30 %. Newly therapies are
urgently needed to improve the prognosis for TNBC
patients. Actually, TNBCs exhibit a high level of molecu-
lar heterogeneity without high-frequency driver muta-
tions. About 60–70 % of TNBCs has mutations of p53.
For PIK3CA mutations, it would be 11 %. No other
mutations were believed as highly prevalent driver in
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TNBCs, which hampered the development of targeted
therapy for TNBCs. So far, some new regimes such as
anti-androgens, anti-mitotic, PI3KCA pathway inhibitors
and so on, had been tested in TNBC. Here, we focus on
the key survival pathway, mitogen-activated and extra-
cellular signal-regulated kinase kinase (MEK)/extracellu-
lar signal-regulated kinase (ERK), which modulated by
epidermal growth factor receptor(EGFR) [3, 4]. Over-
expression of the EGFR is one of the key pathway regu-
lating the proliferation and survive of cells. Hence, these
genes may be good choose as therapeutic targets for
TNBC [5]. Infante performed a phase Ib clinical study to
determine the safety, tolerability, clinical activity and
steady-state pharmacokinetics of trametinib, an oral
MEK inhibitor, in combination with gemcitabine on
breast cancer [6]. The results showed that trametinib
combined with gemcitabine is safe and effective. Selume-
tinib, the benzimidazole ARRY-142886, has been re-
ported to be highly potent MEK inhibitor, with an IC50
of 12 nmol/L against purified MEK [7]. There were
many phase I and phase II clinical studies about Selume-
tinib on melanoma, colorectal cancer (CRC), non-small-
cell lung cancer (NSCLC) and others, for its favorable
toxicity [8–10]. Selumetinib also produces clinically
meaningful increases in iodine uptake and retention in a
subgroup of patients with radioiodine-refractory thyroid
cancer [11]. We considered that Selumetinib might be
potential drug for preventing TNBC metastasis and
recurrence in a preclinical setting.
In the current study, we first found that Selumetinib
inhibited proliferation and migration in two triple-
negative breast cancer cell lines. Then we investigated
its probable mechanism of action. MicroRNAs (miR-
NAs) [12] , 20–22 bp non-coding RNA, had been the
hot are of cancer research for its post-transcriptional
regulation function, which invovled a wide variety of
biological processes, such as proliferation, differenti-
ation, apoptosis, cell cycle and so on [13]. So far many
miRs had been reported took part in MEK/ERK signal-
ing pathway, including miR-768-3p [14], miR-221 [15],
miR-199a/b-3p [16], and so on. Here, we treated TNBC
cell lines HCC1937 and MDA-MB-231 with Selumetinib,
and our founding indicated miR-302a/CUL1 maybe one
significant downstream factors. The miR-302-367 cluster
is over-expressed in embryonic stem and some kinds of
carcinoma cells [17]. It works as anti-oncogene in many
kinds of tumor cells, its overexpression could be of
therapeutic value [18]. Kaid show that miR-302a regu-
lated cell proliferation and self-renewal of esophageal
cancer stem-like cells [19]. Here we found after treated
with Selumetinib miR-302a, an well known ‘bona fide’
tumor suppressor, up-regulated markedly. It is difficult
and costly to verified the gene regulatory networks. The
bioinformatic methods offered the convenient to predicte
possible diagram between miRNAs and their targets.
The most publiced programs are TargetScan, miRanda,
Tarbase, miRecords, RNAhybrid, and so on [20–23].
Here we found CUL-1 is the directly target of miR-302a.
CUL-1 is a essential components of the p19(SKP1)/
p45(SKP2)/CUL-1 complex, named SCF, as the scaffold
element [24]. Previous researches suggest that SCF as
ubiquitin ligase is the key factor to cell cycle and survival.
Aberrant expression of CUL-1 is critical for tumorigen-
esis, such as lung cancer [25], gastric cancer [26]. In the
present study, we found CUL-1 also demonstrate an onco-
genic activity of the OS.
Methods
Cell culture and cell proliferation assay
After planted in 96- or 6-well plates (Corning, USA)
using DMEM with 10 % fetal bovine serum (FBS) at
37 °C in humidified 5 % CO2, HCC1937 and MDA-
MB-231 cells were exposed for 24 h to various doses
of Selumetinib(Sigma-Aldrich, Louis, MO). For the
transfected process, cells were with starved in DMEM
without FBS for 6 h, then miR-302a-AMO, miR-302a-
MIMIC, NC or pcDNA3.1-CUL1 were added with
Lipofectamine 2000 Reagent (Invitrogen) following the
manufacturer’s protocol. Cell proliferation assays were
performed with tetrazolium salt (MTT) array according to
the manufacturer’s protocol.
Evaluation of cell apoptosis by tunnel and FCM
For FCM detection, the procedures were same as the cell
culture previously. All cells of each group were collected
and stained with Annexin V/PI following the instruction(-
BioVision, Palo Alto, CA, USA) The resulting was analyzed
using CellQuest software (Becton Dickinson, San Jose, CA).
For tunnel test, the conditions were little different.
First, cells were cultured with or without IC50 Selumeti-
nib. For the rescue test, we first transferred the miR-
302a AMO or pcDNA3.1-CUL1 or the negative control
for 6 h, then we changed the medium which contain the
10 μM Selumetinib. Visualized apoptotic cells were la-
beled with the In Situ Cell Death Detection kit (Roche)
to detected positive ratio of terminal deoxytransferase-
mediated dUTP-biotin nick end labelling (TUNEL)
following to the manufacturer’s recommendations.
Cell cycle analysis
The procedure was the same as that described previously
for cell culture. After washed with phosphate-buffered sa-
line (PBS), all cells were fixed with 70 % ethanol at −20 °C
for 24 h. Then washed the cell with PBS/1 % BSA again,
stained with 30 μg/ml propidium iodide containing
0.25 mg/ml RNase A for 0.5 h in the dark, and calculated
the cell cycle process ratio by FCM using Cell FIT softwar-
e(Becton Dickinson, San Jose, CA).
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Wound-healing assay
In order to evaluated the motility change of TNBC cells
with Selumetinib, wound healing/scratch assay was per-
formed. TNBCs were seeded in six-well plates overnight,
then scraped the confluent cell monolayer using a 200 μL
sterile pipette tip. After wased with PBS twice then cul-
tured with new DMEM medium (including 10 % FBS with
or without IC50 Selumetinib). For the rescue test, we first
transferred the miR-302a ASO or pcDNA3.1-CUL1 or the
negative control for 6 h, then we made the wound. The
newly mediums contain the 10 μM Selumetinib. 48 h
later, photo images of the plates were photographed.
Cell migration assay
For the migration assay, 1.0 × 105 HCC-1937 or MDA-
MB-231 cells were seeded in 24-well transwell insert
(pore size 8 μm; Corning, Inc., Corning, NY). The cul-
ture conditions were equal to above. After incubated for
12 h, the cells adhering in the lower layer of insert were
fixed and stained with 0.1 % crystal violet. Photographed
under light microscope at 200 ×magnification.
Detection of differentially expressed miRNAs by miRNA
microarray
HCC-1937 cells treated with or without Selumetinib at
its IC50 for 24 h were harvested and subsequently ana-
lyzed using a miRNA microarray (Kangcheng Biotech
Company, Shanghai, China). Briefly, total miRNA was
labeled, hybridized according to manufacturer’s protocol.
The slides were scanned by an Axon GenePix 4000B
microarray scanner. Data filtering, log2 transformation,
and miR normalization hot map were provided by Kang-
cheng Com.
Targeted in vitro luciferase reporter assay
Luciferase reporter assay using the psi-Check2 plasmid
was performed as described previously to detected the
interact between the miR and target [27]. The sequences
used to create the wild Check2-CUL1 constructs were as
follows: forward 5′-AACTCGAGGACCCGCAGCAAAT
AGTTCA-3′ (XhoI site in bold) and reverse 5′ AATGC
GGCCGCCAATGTTCAGCGTAACCCAA-3′ (NotI site
in bold).
Fig. 1 Selumetinib regulates apoptosis and the cell cycle in breast cancer cells. a Selumetinib inhibited the viability of TNBC. After exposure to various
concentration (from 1 to 50 μM) of Selumetinib for 24 h, the proliferation inhibited ratios of HCC-1937 and MDA-MB-231 were determined using the
MTT assay. The formula is Inhibition ratio = (1- Experimental OD / Control OD)*100 %. For the untreated control group, the inhibition ratio is 0(For
HCC1973 cells, the inhibition ratios are 18.53 ± 5.75, 30.57 ± 6.89, 42.83 ± .89, 42.8ition ratios are 18.53n For MDA-MB-231 cells, the inhibition ratios are
17.83 ± 8.43, 27.27 ± 7.41, 37.57 ± 5.65 and 68.53 ± 7.71 respectively. *P < 0.001 compared with the untreated control group.). b HCC-1937 and MDA-
MB-231 cells were treated with 1–50 μM Selumetinib for 24 h. It showed statistical analysis of the living cell ratio using Annexin V and PI stain by FASC
method. The living cell is the double negative cells in the third quadrant (For HCC1973 cells, the living cells ratios are 86.67 ± 4.51, 73.67 ± 9.07, 59.93 ±
9.46 and 47.03 ± 10.57 respectively. For MDA-MB-231 cells, the living cells ratios are 86.23 ± 7.29, 70.53 ± 15.74, 56.73 ± 7.94 and 50.13 ± 8.48 respectively.
*P < 0.01 compared with the untreated control group) c HCC-1937 and MDA-MB-231 cells were treated as b. The cells were stained with PI only, and
the cell cycle distribution was determined using FACS too. The statistical analysis show the cells were arrest in G1 stage (For HCC1973 cells, the G1
ratios are 57.03 ± 5.93, 62.39 ± 7.44, 67.21 ± 1.92 and 77.69 ± 2.21 respectively vs 48.277vely. For MDA-MB-231 cells, the G1 ratios are 55.29 ± 3.66, 65.27
± 2.84, 70.33 ± 1.06 and 75.84 ± 2.92 respectively vs 47.16 ± 4.07. *P < 0.01 compared with the untreated control group). d Tunnel method was used to
detect the apoptosis too. In Selumetinib group, there were brown particles in positive cell. e Wound-healing assay showed untreated cell
rapidly closed the scratch wounds compared with the IC50 dose of Selumetinib. f Transwell migration assays indicated that the Selumetinib
resulted in significant reduction of cell migration
Zhou et al. BMC Cancer  (2016) 16:818 Page 3 of 9
Quantitative real-time PCR of miR-302a and CUL1
expression
Total RNA of each group were abstracted with Trizol.
The primer of miR-302a was purchased from Jima
Com(Shanghai, China). The primers of CUL1 and its
substrates TIMP and TRAF2 were as follow. The QRT-
PCR method was performed as described previously to
detected the interact between the miR and target [27].
Western blot analysis
The total protein were lysed in RIPA buffer and ex-
tracted. 10 % SDS polyacrylamide gel was used to sepa-
rated the proteins. After blocking with 5 % fat-free milk
for 1 h, the membranes were incubated with antbody of
CUL1 (mouse monoclonal; Invitrogen, USA), TIMP
(Rabbit monoclonal; Cell Signaling Technology, MA) or
TRAF2 (Rabbit polyclonal, Abcam, USA) overnight at
4 °C. Blots were washed with PBST and incubated with
the secondary antibody for 1 h. Took the photo using
enhanced chemiluminescence.
siRNA targeting CUL1
Designed and synthetized siRNA-CUL1(5′-CUAGAUAC
AAGAUUAUACAUGCGG-3′) or the control GAPDH-



















Fig. 2 Selumetinib up-regulates miR-302a and down-regulated CUL1 in TNBC cells. a Microarray analysis was used to compare the expression
profiles of 703 miRNAs in HCC-1937 cells that were untreated or treated with Selumetinib. MiR-302a, one of most markedly up-regulated miRs, is
labeled with a red box. b As detected by qRT-PCR, the miR-302a levels were dramatically increased by approximately 2- to 5-fold in the dose-
dependent manner in Selumetinib groups compared with the untreated group. (For HCC1973 cells, the miR-302 levels are 2.03 ± 0.41, 3.33 ± 1.12,
4.03 ± 0.61 and 4.53 ± 0.41 respectively. For MDA-MB-231 cells, the miR-302 levels are 1.97 ± 0.47, 3.13 ± 0.67, 3.87 ± 0.47 and 4.41 ± 0.56 respectively.*P
< 0.01 compared with the untreated control group, which is 1.). c The selection criteria of the miRNA targets were based on their common detection
in the target prediction online databases as well as the full complementarity between the seed region of miR-302a and the 3′UTR of CUL1. d HEK 293
cells were co-transfected with miR-302a-MIMIC, psi-Check2, WT-psi-Check2-CUL1 or MUT-psi-Check2-CUL1. The luciferase activity levels were measured
24 h after transfection. The results from at least three independent experiments are presented as the means ± SE. In this panel, the luciferase assay
results show the regulation of CUL1 by miR-302a (For Wt group, after transfect the miR-302 the luciferase activity was only 0.27 ± 0.05. As for mutated
the first seed sequence, the luciferase activity was 0.62 ± 0.07. As for mutated the second seed sequence, luciferase activity was 0.57 ± 0.04. *P < 0.01
compared with the control group, which is 1.). e The CUL1 mRNA level was reduced with the exposed under Selumetinib in dose-dependent manner
(For HCC1973 cells, the CUL1 levels are 0.81 ± 0.04, 0.63 ± 0.08, 0.43 ± 0.14 and 0.23 ± 0.07 respectively. For MDA-MB-231 cells, the CUL1 levels are 0.78
± 0.07, 0.64 ± 0.11, 0.37 ± 0.07 and 0.24 ± 0.05 respectively.*P < 0.01 compared with the untreated control group, which is 1.). f The change of CUL1
protein has showed a similar trend
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Construction of the CUL1 plasmid
The CUL-1 gene was cloned into pcDNA3.1 plasmid
using the primer of CUL-1 sense 5′-CAGGATCCCGTC
AACCCGGAGCCAGA-3′ (BamHI site in bold) and
antisense 5′-AAGCGGCCGCAGAAGGGWAGCCMG-
3′ (NotI site in bold).
Results
Selumetinib inhibited proliferation and migration in TNBC
cells
Selumetinib has shown the particularly exciting thera-
peutic effect on many kinds of cancer. Cell proliferation
was assessed in HCC1937 and MDA-MB-231 cells. Selu-
metinib reduced the viability ratio of both two TNBCs
in dose-dependent manner (Fig. 1a). The IC50 of Selu-
metinib for HCC1937 and MDA-MB-231 were 15.65
and 12.94 respectively. Apoptosis and cell cycle arrest
are the main reason for the inhibition of cell growth.
Here we found Selumetinib trigged apoptosis and arrest
of G1 stage in dose-dependent manner too (Fig. 1b, c
and d). Moreover, we explored the effect of Selumetinib
on cell mobility. Compared with the control group,
TNBCs with IC50 of Selumetinib slowly closed the
scratch wounds (Fig. 1e). he Fig. 1f showed that Selume-
tinib treatment led to significantly decreased in cell mi-
gration ability than the untreated control cells.
Selumetinib up-regulated miR-302a and down-regulated
CUL1 expression
miRs are involved in regulating gene transcription and cell
biological function. Here we detected the change of miRs
in MDA-MB-231 treated with Selumetinib. miRNA array
analysis showed miR-302a(sequence: GUGAAAUGUU
UAGGACCACUAG) raised 3.856 times (Fig. 2a). Further-
more we verified the expression level of miR-302a was
markedly and stable up-regulated in TNBCs by QRT-PCR
(Fig. 2b). For miR-302a, it had been considered as a tumor
suppressor [28]. A series of bioinformatics software made
it easier to look for targets of miRs. miRanda show there
was two combine seed sequence between miR-302a and
the 3′-UTR of CUL1 (Fig. 2c). To determine whether
CUL-1 is the functional target of miR-302a, we con-
structed WT or MUT psiR-CHECK2-CLU-1 recombinant
plasmid. After transfected miR-302a-MIMIC and the
plasmids in 293 T cells for 48 h, the luciferase re-
porter activity was detected. The luciferase activity of
Fig. 3 Knocked-down the CUL1 lead to the same effect of Selumetinib. a The siRNA could effective inhibited the CUL1 expression on mRNA
levels (For HCC1973 cells, the CUL1 level was 0.23HCC19. For MDA-MB-231 cells, the CUL1 level was 0.22 ± 0.04.*P < 0.01 compared with the NC
group, which is 1.). b After silencing the CUL1, the TIMP1 level was increased (For HCC1973 cells, the TIMP1 level was 2.81 ± 0.75. For MDA-MB-
231 cells, the TIMP1 level was 2.41 ± 0.23.*P < 0.01 compared with the NC group, which is 1.). c The tendency of TRAF2 mRNA expression levels in
MDA-MB-231 and HCC-1937 cells were equal to TIMP1 determined by QRT-PCR (For HCC1973 cells, the TRAF2 level was 2.38 ± 0.45. For MDA-MB-
231 cells, the TRAF2 level was 2.29 ± 0.33. *P < 0.01 compared with the NC group, which is 1.). d the CUL1, TIMP1 and TRAF2 protein expression
levels in HCC-1937 and MDA-MB-231 cells were examined by WB analysis. e After transfected the siRNA-CUL into HCC-1937 and MDA-MB-231
cells, the cell proliferation ratio was inhibited significantly (For HCC1973 cells, the viability ratio was 0.55 ± 0.06. For MDA-MB-231 cells, the viability
ratio was 0.53 ± 0.15. *P < 0.01 compared with the NC group, which is 1.). f the Tunnel analysis clarified this negative effect of siRNA-CUL1.
g The transwell analysis showed, the numbers of the migrated cells in the NC group of both two TNBC cells, are almost double that are in the
siRNA-CUL1 group h. The wound-healing assay showed the cell migration ability was reduced observably in siRNA-CUL1 group. For the NC
group, the gap closure rate is more than two to thirds in both HCC-1937 and MDA-MB-231 cells. For siRNA-CUL1 group, the gap closure rate
is less than one thirds
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WT Check2-CUL1 was reduced to approximately 35–
40 % of control group(P < 0.001 Fig. 2d). Conversely,
there were no statistical difference between MUT
group and control. What is the effect of Selumetinib
on CUL-1, Fig. 2e and f described that Selumetinib
reduced both mRNA and protein level of CUL-1 in
dose-dependent manner. It is the reversely changes
to miR-302a, which also proved miR-302a negative
regulated CLI-1 indirectly.
CUL1 regulated the degradation of key regulatory
proteins
In order to clarify the CUL1 play important role in Selu-
metinib on TNBC cells, we further detected the change of
two downstream substrates of Cul-1, TIMP1 and TRAF2.
First we knock down the CUL1 by siRNA. QRT-PCR and
WB results show the siRNA effectively silencing the
CUL1 expression and lead to TIMP1 and TRAF2 up-
regulating (Fig. 3a to d). Equal to our hypothesis, as soon
Fig. 4 Characterization of cells transfected with miR-302a-AMO and the CUL1 expression plasmid. After transfected miR-302a-AMO or the
pcDNA3.1-CUL1 plasmid in HCC-1937 and MDA-MB-231 cells for 6 h, HCC-1937 and MDA-MB-231 cells were exposed on Selumetinib (10 μM).
The CUL1 mRNA (a) and protein (b) expression levels were detected by qRT-PCR and western blot analysis, respectively. The CUL-1 level on both
mRNA and protein increased significantly in miR-302a-AMO and pcDNA3.1-CUL1 group (For HCC1973 cells, the CUL1 levels were 0.97 ± 0.08, 3.81
± 1.17 and 14.18 ± 3.56 respectively. For MDA-MB-231 cells, the CUL1 levels were 0.95 ± 0.15, 3.86 ± 0.77 and 17.44 ± 4.71 respectively. *P < 0.01
compared with the Selumetinib control group, which is 1). c Cell viability was detected by MTT method after single or combined treatment with
Selumetinib and miR-302a-AMO or the pcDNA3.1-CUL1 plasmid (For HCC1973 cells, the inhibition ratio were 53.72 ± 8.34 vs 55.07 ± 7.83, 38.17 ±
4.89 and 36.73 ± 6.11 respectively. For MDA-MB-231 cells, the inhibition ratio were 54.83 ± 7.81 vs 55.33 ± 5.43, 41.11 ± 5.47 and 37.27 ± 4.25
respectively. *P < 0.01 compared with the Selumetinib control group). d Change in the apoptotic ratio of was HCC-1937 and MDA-MB-231 cells
were detected by FACS (For HCC1973 cells, the living cell ratio were 55.07 ± 7.61 vs 52.33 ± 11.52, 73.27 ± 7.26 and 68.03 ± 10.95 respectively. For
MDA-MB-231 cells, the living cell ratio were 55.37 ± 5.51 vs 50.53 ± 11.91, 76.43 ± 10.21 and 71.82 ± 14.07 respectively. *P < 0.01 compared with the
Selumetinib control group). e As soon as the same treatment on HCC-1937 and MDA-MB-231 cells, the cell cycle arrest was in line with apoptosis
trends ((For HCC1973 cells, the G1 ratios are 69.53 ± 5.35 vs 69.02 ± 7.28, 62.33 ± 8.27 and 60.86 ± 10.69 respectively. For MDA-MB-231 cells,
the G1 ratios were 72.53 ± 2.91 vs 72.94 ± 7.55, 62.53 ± 9.33 and 60.56 ± 9.33 respectively. *P < 0.01 compared with the Selumetinib control
group). f Another apoptosis detected method, tunnel, produced the identical results. g and h indicated the negative effect of Selumetinib
on migration of HCC-1937 and MDA-MB-231 were reverse by miR-302a-AMO and CUL1 over-expression plasmid
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as the CUL1 were knocked down, the cell proliferation
and migration were reduced (Fig. 3e to g).
Adjusted miR-302a/CUL1 level reversed the effect of
Selumetinib
In order to more deeply investigate the miR-302a/CUL-1
pathway is relevance of Selumetinib effect. We over-
expressed CUL1 with pcDNA3.1-CUL1 plasmid and inhib-
ited miR-302a with its AMO oligonucleotide, which
induced up-regulating of CUL1 on both the mRNA and
protein level (Fig. 4a and b). The effect of Selumetinib on
TNBCs was reversed by miR-302a-AMO and pcDNA3.1-
CUL1 plasmid. For the inhibition of viability, in both
HCC1937 and MDA-MB-231 cells, the miR-302a-AMO
and pcDNA3.1-CUL1 group were 1.63- to 2.3-fold lower
than other two control groups (Fig. 4c). The ratio of apop-
tosis and G1 stage were alos lower than two control groups
(Fig. 4d to f). The Wound-healing assay and transwell test
showed the migration inhibited effect of Selumetinib on
HCC1937 and MDA-MB-231 were reverse by miR-302a-
AMO and CUL1-overexpressed plasmid (Fig. 4g, h).
Discussion
Aberrant activation of RAS/Raf/MEK/ERK signaling path-
ways had been reported in many kinds of cancer and been
considered as targeted for its oncogenic effect. Not only
pre-clinically but also many phase I or II clinical trial had
been displayed the obvious therapeutic effects in solid
tumor [27–29]. Some research reported that BRAF muta-
tion was closely related to the sensitivity of Selumetinib
[30]. Chen found that Selumetinib selectively rescued
primary glial progenitors from TMX toxicity, such as
cognitive dysfunction and changes in CNS metabolism,
hippocampal volume, and brain structure, in vitro while
enhancing TMX effects on MCF7 [31]. MEK pathway also
plays key role in TNBC. Here, we found MAP/ERK kinase
(MEK) 1/2 inhibitor, Selumetinib, repress the viability and
induced apoptosis of HCC1937 and MDA-MB-231 in a
dose-dependent manner. The G1 arrest and mobility
declined were also linked to dose of Selumetinib (Fig. 1a
to d). Then we goes deeply into the mechanism. We
screened miRNA profile of MDA-MB-231 with or with-
out Selumetinib (Fig. 2a). miR-302a was significantly
and gradually up-regulated miRNAs with the concen-
tration of Selumetinib in both MDA-MB-231 and
HCC-1937 (Fig. 2b). We focus on microRNA (miR)-302
family for its tumor supperessor function in many kinds
of tumor [32, 33]. Yan reported miR-302 was important to
miRNA-induced pluripotent stem cells (mirPS) of endo-
metrial cancer cell lines, take part in the inhibition of cell
proliferation and tumorigenicity [34]. Previous papers re-
vealed that miR-302a regulated the expression of AKT1
[35], NR2F2 [36], CDK2 [37] and so on targeted genes. By
targetscan, we predicted there were two complementary
sequences in the miR-302a and 3′UTR-CUL1 (Fig. 2c).
Luciferase reporter assay showed miR-302a negative regu-
lation of CUL1 directly (Fig. 2d). According to Fig. 2e and
f, it was confirmed that CUL1 level was closed related
with Selumetinib concertration. CUL1 is a key component
of SCF ubiquitin ligases [38]. SCF promotes the ubiquiti-
nation and degradation of a broad range of proteins in-
volved in cell cycle progression, signal transduction and
transcription. As a key member of SCF, CUL1 is over-
expressed in many kinds of cancer [39–41] and represent
as target molecular for therapy [42–44]. In this paper, we
found Selumetinib could inhibit both proliferation and
migration in TNBC cells, and miR-302a/CUL maybe the
key factor in this process. So we assume that it is equal to
Selumetinib that we knocked down the CUL1 in TNBC
cells. We also choose tow substrate, TIMP1 and TRAF2 of
CUL1 to clarify this hypothesis. As expected, after silen-
cing the CUL1, the viability and migration ability of
TNBC cell were reduced markedly. For further prove
miR-302a/CUL-1 is the operator nodes of Selumetinib
onTNBCs. We regulated the miR-302 or CUL-1 level
using miR-302a-AMO or CUL1 over-expression plasmid
respectively in HCC1937 and MDA-MB-231 cells. Figure 4
indicated the effect of Selumetinib reversed accompany
with raising of CUL-1 and silencing of miR-302a.
Conclusion
MEK pathway has been shown over-activated in TNBC.
Based on our results, MEK1/2 inhibitor, Selumetinib,
reduced viability through inducing apoptosis and G1
arrest, meanwhile the inhibition of mobility by Selume-
tinib was also be found in TNBCs. In these processes,
we indicated miR-302a/CUL1 work as critical pathway
in Selumetinib on TNBC.
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